Clinical trial

Pharmacokinetics, Safety and Efficacy of HR020602 Injection in Children Undergoing General Anesthesia

Name
HR020602-201
Description
This study is divided into two stages: the first stage is a dose verification trial, with a multicenter, open, single arm trial design, which is planned to enroll 10 children with general anesthesia surgery (all using HR020602 injection); If the result shows that the dose is low, 10 children under general anesthesia will be included again for higher dose verification.The second stage is designed as a multicenter, randomized, double-blind, parallel control trial with positive drugs, which is planned to include 25 children with general anesthesia surgery in the test group and 25 children in the control group. There should be at least 20 patients in each of \[2,12\] and \[12,18)age groups.
Trial arms
Trial start
2021-06-07
Estimated PCD
2023-08-15
Trial end
2023-08-15
Status
Completed
Phase
Early phase I
Treatment
HR020602 injection
HR020602 injection
Arms:
HR020602 injection
fentanyl injection ; remifentanil injection
fentanyl injection + remifentanil injection
Arms:
fentanyl injection + remifentanil injection
Size
70
Primary endpoint
The success rate of anesthesia induction
Within 5 minutesafter propofol medium /long chain fat emulsion administration
Eligibility criteria
Inclusion Criteria: 1. 2 years old ≤age\<18 years old, regardless of gender; 2. General anesthesia is planned; 3. ASA score grade I \~ II; 4)Able to sign the informed consent. Exclusion Criteria: 1. Children with general anesthesia contraindications; 2. With diseases that are not suitable for the study in the scheme; 3. Abnormal liver and kidney function in screening stage; 4. Abnormal coagulation function; 5. Serum electrolyte abnormality; 6. Subjects intolerant or allergic to the study drugs; 7. Recently received other narcotic drugs or other drugs that affect the metabolism of study drugs; 8. The child thought to be unsuitable for the study, as determined by the investigator.
Protocol
{'studyType': 'INTERVENTIONAL', 'phases': ['PHASE2'], 'designInfo': {'allocation': 'RANDOMIZED', 'interventionModel': 'PARALLEL', 'interventionModelDescription': 'This study is divided into two stages: the first stage is a dose verification trial, with a multicenter, open, single arm trial design, which is planned to enroll 10 children with general anesthesia surgery (all using HR020602 injection); If the result shows that the dose is low, 10 children under general anesthesia will be included again for higher dose verification. The second stage is designed as a multicenter, randomized, double-blind, parallel control trial with positive drugs, which is planned to include 25 children with general anesthesia surgery in the test group and 25 children in the control group. There should be at least 20 patients in each of \\[2,12\\] and \\[12,18)age groups.', 'primaryPurpose': 'TREATMENT', 'maskingInfo': {'masking': 'QUADRUPLE', 'whoMasked': ['PARTICIPANT', 'CARE_PROVIDER', 'INVESTIGATOR', 'OUTCOMES_ASSESSOR']}}, 'enrollmentInfo': {'count': 70, 'type': 'ACTUAL'}}
Updated at
2024-03-04

1 organization

2 products

1 indication

Product
HR020602
Product
Fentanyl